◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › L › LXRX

Lexicon Pharmaceuticals Inc (LXRX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-18

Lexicon Pharmaceuticals Inc (LXRX) operates in the BIOTECHNOLOGY industry and is headquartered in The Woodlands, United States with about 81 employees. Its market capitalization is roughly $912 million. In the fiscal year ended 2025-12-31, LXRX reported $50M in revenue and ($50M) in net income.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.

Interactive charts & full statements → Open the LXRX valuation workbench →

LXRX Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$41M	$50M	$31M	$1M	$0M	$0M	$24M	$322M	$63M	$90M	$83M	$130M	$23M	$2M	$1M	$2M	$5M	$11M	$32M	$50M	$73M
Gross Profit	$41M	$50M	$30M	($58M)	($52M)	($55M)	$22M	$319M	$61M	$88M	($81M)	$35M	($66M)	($87M)	($81M)	$2M	$5M	$11M	$32M	$50M	$73M
Gross Margin %	100.0%	99.5%	98.0%	-4798.0%	-37681.3%	-18371.8%	92.0%	99.0%	96.1%	97.9%	-96.8%	26.8%	-290.6%	-3936.1%	-7482.6%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	($55M)	($49M)	($197M)	($172M)	($101M)	($87M)	($48M)	$141M	($103M)	($137M)	($137M)	$1M	($100M)	($102M)	($108M)	($114M)	($96M)	($90M)	($97M)	($75M)	($55M)
Operating Margin %	-134.1%	-98.2%	-634.2%	-14264.9%	-72489.2%	-29224.8%	-199.2%	43.9%	-163.4%	-151.3%	-164.6%	1.1%	-439.2%	-4607.2%	-9955.5%	-6170.6%	-1950.2%	-840.7%	-298.7%	-149.6%	-75.9%
Net Income	($62M)	($50M)	($200M)	($177M)	($102M)	($88M)	($59M)	$130M	($121M)	($129M)	($141M)	($5M)	($100M)	($104M)	($110M)	($116M)	($102M)	($83M)	($77M)	($59M)	($54M)
Net Margin %	-151.2%	-101.1%	-644.8%	-14710.9%	-73341.0%	-29449.0%	-244.1%	40.4%	-190.7%	-142.9%	-169.7%	-3.6%	-438.8%	-4686.1%	-10120.4%	-6285.3%	-2073.7%	-773.6%	-237.8%	-117.3%	-74.6%
EBITDA	($51M)	($41M)	($184M)	($170M)	($100M)	($87M)	($41M)	$148M	($96M)	($125M)	($126M)	$12M	($96M)	($99M)	($104M)	($109M)	($94M)	($84M)	($86M)	($65M)	($40M)
Earnings Per Share (EPS)	$-0.15	$-0.14	$-0.63	$-0.80	$-0.62	$-0.60	$-0.53	$1.11	$-1.14	$-1.23	$-1.36	$-0.05	$-1.31	$-1.42	$-1.58	$-2.39	$-2.35	$-3.98	$-3.93	$-4.12	$-5.68
Shares Outstanding (M)	438M	363M	320M	221M	166M	146M	111M	117M	106M	105M	104M	104M	76M	73M	70M	49M	43M	21M	20M	14M	10M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LXRX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$1M	$21M	$5M	$14M	$29M	$1M	$27M	$2M
Gross Profit	$1M	$21M	$5M	$14M	$29M	$1M	$1M	$2M
Gross Margin %	94.4%	99.5%	94.2%	99.9%	99.3%	97.6%	2.3%	95.9%
Operating Income (EBIT)	($27M)	($1M)	($15M)	($12M)	$4M	($26M)	($33M)	($64M)
Operating Margin %	-3835.3%	-4.7%	-269.1%	-85.9%	12.9%	-2034.8%	-123.3%	-3639.6%
Net Income	($32M)	($1M)	($16M)	($13M)	$3M	($25M)	($34M)	($65M)
Net Margin %	-4591.8%	-4.9%	-282.7%	-90.0%	11.3%	-2004.4%	-127.2%	-3703.5%
EBITDA	($29M)	$1M	($13M)	($10M)	$6M	($23M)	($20M)	($60M)
Earnings Per Share (EPS)	$-0.07	$-0.00	$-0.04	$-0.04	$0.01	$-0.07	$-0.09	$-0.18
Shares Outstanding (M)	438M	400M	363M	363M	364M	362M	361M	361M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LXRX Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	($65M)	($68M)	($179M)	($162M)	($89M)	($87M)	($143M)	$114M	($149M)	($185M)	($176M)	$185M	($76M)	($91M)	($94M)	($88M)	($82M)	($89M)	($96M)	($74M)	($57M)
Capital Expenditures (CapEx)	$0M	$0M	$1M	$0M	$1M	$1M	$0M	$0M	$0M	$0M	$0M	$1M	$0M	$2M	$0M	$1M	$1M	$0M	$2M	$2M	$4M
Free Cash Flow (FCF)	($65M)	($68M)	($180M)	($162M)	($90M)	($88M)	($143M)	$114M	($149M)	($186M)	($176M)	$184M	($76M)	($93M)	($95M)	($89M)	($84M)	($89M)	($98M)	($76M)	($60M)
FCF Margin %	-158.5%	-136.2%	-578.5%	-13485.6%	-64875.5%	-29610.1%	-596.2%	35.3%	-235.2%	-205.5%	-211.0%	141.4%	-331.2%	-4176.4%	-8719.2%	-4821.2%	-1701.3%	-835.4%	-302.6%	-152.1%	-83.1%
Dividends Paid	—	—	—	$100M	—	$12M	$217M	—	—	$0M	$2M	$0M	$0M	$0M	$1M	$4M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LXRX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($9M)	($15M)	($17M)	($24M)	$17M	($44M)	($21M)	($54M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($9M)	($15M)	($17M)	($24M)	$17M	($44M)	($22M)	($54M)
FCF Margin %	-900.0%	-69.8%	-313.7%	-168.1%	58.9%	-3468.9%	-82.7%	-3081.5%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LXRX Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$250M	$185M	$298M	$229M	$194M	$137M	$204M	$418M	$284M	$437M	$476M	$655M	$471M	$274M	$372M	$431M	$367M	$258M	$262M	$369M	$190M
Cash & Cash Equivalents	$41M	$34M	$67M	$22M	$46M	$64M	$126M	$36M	$160M	$311M	$347M	$521M	$339M	$129M	$223M	$282M	$47M	$101M	$86M	$23M	$30M
Total Liabilities	$76M	$77M	$152M	$136M	$77M	$23M	$47M	$301M	$311M	$384M	$318M	$369M	$187M	$104M	$105M	$133M	$120M	$94M	$66M	$83M	$105M
Total Debt (Short + Long-Term)	$53M	$56M	$101M	$101M	$50M	$1M	$12M	$246M	$229M	$234M	$69M	$81M	$98M	$14M	$15M	$48M	$28M	$67M	$30M	$31M	$32M
Total Shareholders' Equity	$175M	$108M	$146M	$93M	$117M	$114M	$156M	$117M	($1.5B)	$52M	$157M	$286M	$284M	($1.0B)	$267M	$298M	$247M	$164M	$186M	$256M	$86M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive LXRX viewer.

Other Companies in BIOTECHNOLOGY

SGP · SpyGlass Pharma, Inc. — $973 million
SLBT · SL Science Holding Limited Ordinary Shares — $965 million
SLDB · Solid Biosciences LLC — $955 million
SANA · Sana Biotechnology Inc — $928 million
HELP · Cybin Inc. Common Stock — $904 million
IMMX · Immix Biopharma Inc — $894 million
FTH · Faeth Therapeutics, Inc. — $891 million
TBPH · Theravance Biopharma Inc — $884 million

← LXP All “L” companies LXS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.